Both Alzheimer’s and Parkinson’s Disease have had exciting recent advancements in treatment, with approvals of the first disease modifying drugs to treat Alzheimer’s Disease and new biomarkers being discovered to advance new therapies for Parkinson’s.

Fully diagnosing Alzheimer’s, Parkinson’s and other dementia-causing disorders, however, is complex and the number of neurologists and dementia specialists is limited, resulting in long wait times for appointments and delayed diagnosis.  No single test diagnoses these diseases, and symptoms similar to Alzheimer’s and Parkinson’s can be caused by conditions other than dementia.

CxPM’s NeuroFirstTM  products can help primary care physicians rule out dementia and differentiate between those patients who would benefit most from further neurological testing and those whose symptoms are very unlikely to be caused by Alzheimer’s dementia or Parkinson’s.  Our blood test will be available to order by your physician in 2024.

As the gatekeepers for our medical system, primary care providers need help determining which patients would most benefit from further specialist evaluation and which ones can be treated by them.

Evidence-based Precision Medicine

Alzheimer’s, Parkinson’s and other dementia-causing disorders reflect many different pathologies.  By testing for a wide range these pathologies, treatment can be targeted more precisely.


Expanded Vision

CxPM technology will be expanded across other neurodegenerative diseases. Using biomarkers and targeted treatment, patients will be treated with the right drugs at the right time.